Based upon a meta-analysis of cardiovascular outcomes in type 2 diabetes studies, findings suggest that a 15% relative risk reduction in nonfatal myocardial infarcts is associated with an A1C reduction of approximately:
Answer: 2. 1.0%
Educational Critique: A meta-analysis of cardiac outcomes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) and Veteran Affairs Diabetes Trial (VADT) found every approximate 1% A1C reduction was positively correlated with a 15% relative risk reduction for myocardial infarct. The A1C benefits did not extend to stroke or all-cause mortality.